An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

Abstract Background Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of glucocorticoid-induced diabetes mellitus. Methods...

Full description

Bibliographic Details
Main Authors: Yoshia Miyawaki, Ken-Ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Katsue Sunahori-Watanabe, Tomoko Kawabata, Jun Wada
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Journal of Medical Case Reports
Subjects:
Diabetes
Glucocorticoid
Dipeptidyl peptidase-4 inhibitor
Online Access:http://link.springer.com/article/10.1186/s13256-018-1817-6

Internet

http://link.springer.com/article/10.1186/s13256-018-1817-6

Similar Items